IRAK4 Degraders for Neurological Disorders and Beyond

The present inventive concept expands the application of IRAK4 degraders beyond MYD88-mutant B-cell lymphomas to treat neurological disorders, neuroinflammation, neurodegenerative diseases, pain disorders, and psychiatric disorders.

While IRAK4 degraders have shown promise in treating MYD88-mutant B-cell lymphomas, there remains a significant unmet need for effective treatments of neurological disorders, which are often characterized by inflammation and immune dysregulation. The original patent's IRAK4 degraders were not designed to address these conditions, leaving a gap in the treatment landscape.

The present inventive concept utilizes IRAK4 degraders, similar to those disclosed in the original patent, but configured to selectively degrade IRAK4 protein and modulate the immune response in the brain. This is achieved through the administration of an IRAK4 degrader, which can be formulated as a composition with a neuroprotective agent, to patients in need thereof. The IRAK4 degrader inhibits IRAK4-mediated inflammation in the central nervous system, reducing symptoms of neurological disorders. Additionally, the IRAK4 degrader can be used to treat pain disorders by inhibiting IRAK4-mediated pain signaling in the nervous system, and psychiatric disorders by modulating the immune response in the brain.

The new claims are novel and non-obvious because they apply the IRAK4 degrader technology to entirely new indications, including neurological disorders, neuroinflammation, neurodegenerative diseases, pain disorders, and psychiatric disorders. The inventive step lies in recognizing the potential of IRAK4 degraders to modulate the immune response in the brain and address these unmet medical needs.

Alternative embodiments of the inventive concept may include the use of different IRAK4 degraders, formulations, or administration routes. Variations may also include the combination of IRAK4 degraders with other therapeutic agents or modalities to enhance efficacy or reduce side effects.

The present inventive concept has significant commercial potential in the treatment of neurological disorders, neuroinflammation, neurodegenerative diseases, pain disorders, and psychiatric disorders. The target market includes pharmaceutical companies, biotechnology companies, and research institutions focused on developing novel therapies for these indications.